Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.11851/9002
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKüçük, Beyza Nur-
dc.contributor.authorŞimşek, Rahime-
dc.contributor.authorErdemli Köse, Selinay Başak-
dc.contributor.authorYirun, Anıl-
dc.contributor.authorErkekoglu, PInar-
dc.date.accessioned2022-11-30T19:25:49Z-
dc.date.available2022-11-30T19:25:49Z-
dc.date.issued2022-
dc.identifier.issn0731-8898-
dc.identifier.urihttps://doi.org/10.1615/JEnvironPatholToxicolOncol.2022039271-
dc.identifier.urihttps://hdl.handle.net/20.500.11851/9002-
dc.description.abstractOn December 2019, the world faced a new pandemic caused by a novel type of coronavirus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This disease is named as “coronavirus disease 2019 (COVID-19).” This RNA virus infected millions of people around the world causing millions of deaths. It takes approx-imately 8–10 years to develop a new drug and it seems hard to have a specific pharmaceutical agent against COVID-19. So far, there is only one drug that has applied for registration. The drugs used in clinics against COVID-19 were approved for malaria, human immunodeficiency syndrome (HIV), influenza A and B, and other viral diseases. All these drugs for COVID-19 treatment are being applied according to “drug repurposing (drug repositioning)” strategy. However, they could cause some severe adverse effects on susceptible populations. In some cases, patients can survive after dis-ease. However, the adverse effects of these drugs may lead to morbidity and mortality later. In this review, drugs used against COVID-19 in clinics, their mechanisms of action and possible adverse effects on susceptible populations will be discussed. © 2022 by Begell House, Inc. www.begellhouse.com.en_US
dc.language.isoenen_US
dc.publisherBegell House Inc.en_US
dc.relation.ispartofJournal of Environmental Pathology, Toxicology and Oncologyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectdrug repurposing (drug repositioning)en_US
dc.subjectsusceptible populationsen_US
dc.subjectantivirus agenten_US
dc.subjectdrug therapyen_US
dc.subjecthumanen_US
dc.subjectpandemicen_US
dc.subjectAntiviral Agentsen_US
dc.subjectCOVID-19en_US
dc.subjectHumansen_US
dc.subjectPandemicsen_US
dc.subjectSARS-CoV-2en_US
dc.titleAdverse Effects of Covid-19 Treatments: a Special Focus on Susceptible Populationsen_US
dc.typeArticleen_US
dc.identifier.volume41en_US
dc.identifier.issue3en_US
dc.identifier.startpage45en_US
dc.identifier.endpage64en_US
dc.identifier.wosWOS:000921167500002en_US
dc.identifier.scopus2-s2.0-85134591572en_US
dc.identifier.pmid35993955en_US
dc.identifier.doi10.1615/JEnvironPatholToxicolOncol.2022039271-
dc.authorscopusid57812850000-
dc.authorscopusid6602746428-
dc.authorscopusid57448659200-
dc.authorscopusid57211079309-
dc.authorscopusid35239631400-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopusqualityQ3-
dc.ozel2022v3_Editen_US
item.openairetypeArticle-
item.languageiso639-1en-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Öğrenci Yayınları / Students' Publications
Show simple item record



CORE Recommender

Page view(s)

72
checked on Dec 23, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.